Concordance Between Pharmaceuticals and Medical Devices Agency Review and Ministry of Health, Labour and Welfare Decision Among New Drug Applications in Japan
Open Access
- 8 November 2024
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 544-553
Abstract
New drug applications (NDAs) in Japan are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA). Those that pass the review are subsequently subject to deliberation by the Ministry of Health, Labour and Welfare Pharmaceutical Affairs and Food Sanitation Councils (MHLW‐PAFSC), and the MHLW legislatively grants approval based on its positive opinions. However, little is known regarding the relationship between the PMDA review and the MHLW decision. We retrospectively assessed the MHLW decision of NDAs that passed the PMDA review at the initial MHLW‐PAFSC deliberation from 2002 to 2022. The reasoning behind a non‐supportive opinion from the MHLW‐PAFSC and the sponsor's actions to overcome unresolved issues were also documented. A total of 2,117 of 2,153 (98.3%) NDAs that passed the PMDA review were approved at the initial MHLW‐PAFSC deliberation with a positive opinion. The remaining 36 applications were not approved at the initial deliberation and subjected to continued deliberation because of a non‐supportive opinion from the councils, although 29 were finally approved through revision of the application document (24 applications), re‐analysis of the data (1 application), or additional clinical trials (4 applications). Seven applications have not been approved, of which one was refused, four were withdrawn, and two were unknown. The MHLW approves NDAs that passed the PMDA review at the initial deliberation at a high rate, suggesting that NDAs only suitable for approval passed the review and reached the MHLW‐PAFSC deliberation. Only a few NDAs were not approved at the initial deliberation; however, most of them were finally approved.Keywords
This publication has 14 references indexed in Scilit:
- The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022Applied Health Economics and Health Policy, 2023
- Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021JAMA Health Forum, 2023
- Achievements and challenges of the Sakigake designation system in JapanBritish Journal of Clinical Pharmacology, 2021
- Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in JapanBritish Journal of Clinical Pharmacology, 2021
- Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory AnalysisClinical Pharmacology & Therapeutics, 2020
- A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014–2016: Concordance, Discordance, and WhyClinical Pharmacology & Therapeutics, 2019
- Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008–2015The Milbank Quarterly, 2019
- Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional studyBMJ, 2015
- Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012JAMA, 2014
- Analysis of new drugs whose clinical development and regulatory approval were hampered during their introduction in JapanJournal of Clinical Pharmacy and Therapeutics, 2013